Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588878 | 0.88 | MAPT (0.53) | RAB9ANPC1MEN1KMT2AHSP90AA1 | |
| SCHEMBL29376467 | 0.81 | NPC1 (0.47) | RAB9ANPC1MEN1KMT2AHSP90AA1 | |
| SCHEMBL7902671 | 0.80 | MEN1 (0.64) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL2592673 | 0.79 | HSP90AA1 (0.46) | RAB9ANPC1MEN1KMT2AHSP90AA1 | |
| Nifurthiazole SCHEMBL194337 | 0.77 | HSP90AA1 (0.45) | RAB9ANPC1MEN1KMT2AHSP90AA1 | |
| SCHEMBL9621679 | 0.76 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2APOLB | |
| SCHEMBL3344653 | 0.75 | MAPT (0.53) | RAB9ANPC1MEN1KMT2AHSP90AA1 | |
| SCHEMBL15689083 | 0.72 | RAB9A (0.73) | RAB9AMEN1KMT2AMAPTABL1 | |
| SCHEMBL7829031 | 0.71 | RAB9A (0.51) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL16434102 | 0.71 | PAX8 (0.43) | NPC1MEN1KMT2ASLC2A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512034-B1 | METHODS, TERMINAL AND SERVER FOR MANAGING PERSONAL DATA | PIGNELA CAPITAL SA (CH) | 2025-07-23 | — | — | EP | claimed |
| EP-4512034-A1 | METHODS, TERMINAL AND SERVER FOR MANAGING PERSONAL DATA | Pignela Capital SA (CH) | 2025-02-26 | — | — | EP | claimed |
| US-20240052394-A1 | BIOPRODUCTION OF ENANTIOPURE (R)- AND (S)-2-PHENYLGLYCINOL FROM STYRENE AND RENEWABLE FEEDSTOCKS VIA ARTIFICIAL ENZYME CASCADE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-02-15 | — | — | US | claimed |
| WO-2023203291-A1 | METHODS, TERMINAL AND SERVER FOR MANAGING PERSONAL DATA | BLOCS ET COMPAGNIE (FR) | 2023-10-26 | — | — | WO | claimed |
| CN-116829726-A | Biological production of enantiomerically pure (R) -and (S) -2-phenylglycinol from styrene and renewable raw materials by artificial enzyme cascade | 新加坡国立大学 | 2023-09-29 | — | — | CN | claimed |
| US-20260130392-A1 | HIGH PROTEIN FOOD COMPOSITIONS | AIR PROTEIN INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4636401-A2 | METHODS FOR PROFILING THE T-CELL-RECEPTOR REPERTOIRE | The Broad Institute, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12435372-B2 | Methods for profiling the T-cell-receptor repertoire | THE BROAD INSTITUTE, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12408684-B2 | High protein food compositions | AIR PROTEIN, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4597922-A2 | PERSONAL DATA MANAGEMENT METHOD, PERSONAL DATA MANAGEMENT TERMINAL, AND PERSONAL DATA MANAGEMENT SERVER | Pignela Capital SA (CH) | 2025-08-06 | — | — | EP | disclosed |
| EP-1296714-B1 | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. | UNIV IOWA RES FOUND (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090155212-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | BRATZLER ROBERT L | 2009-06-18 | — | — | US | disclosed |
| US-7534772-B2 | Methods for enhancing antibody-induced cell lysis and treating cancer | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-20060211639-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | PFIZER INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1296714-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030026801-A1 | Methods for enhancing antibody-induced cell lysis and treating cancer | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| US-20020156033-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | CD4, VSIG8, FCGR3B | RAB9A 2493/4885NPC1 2993/4885MEN1 3020/4885 |
| US-20260130392-A1 | HIGH PROTEIN FOOD COMPOSITIONS | MAX, QPCTL, CALCB | RAB9A 3978/4885NPC1 3886/4885MEN1 2462/4885 |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | RAB9A 952/4885NPC1 90/4885MEN1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.